CHICAGO – For patients with extensive-stage small cell lung cancer, a first-line treatment of serplulimab plus chemotherapy provided significant benefit and safety profile compared with chemotherapy alone.
“For the past 30 years, etoposide-platinum has been the standard first-line treatment [for small cell lung cancer],” Ying Cheng, MD, professor in the department of thoracic oncology at Jilin Cancer Center in Changchun, China, said during her presentation at ASCO Annual Meeting. “PD-L1 inhibitors plus chemotherapy marked a milestone in the first-line treatment of